

Financial Impact of Integrated Specialty Pharmacy Efforts to Avoid Oral Oncolytic Waste

Brooke Looney, PharmD, CSP; Jared Crumb, PharmD; Gabrielle Jones, PharmD Candidate; Ryan Moore, MS; Leen Choi, PhD; Autumn D. Zuckerman, PharmD, BCPS, AAHIVP, CSP; Kristen Whelchel, PharmD, CSP

Quick Facts

Evaluated the **impact on waste and cost avoidance** associated with specialty pharmacist postponing requesting a prescription renewal in patients on **oral oncolytics** who have an upcoming follow-up and sufficient medication supply



167

renewal requests
postponed after
pharmacist review



13

months




98%

resulted in a
therapy change



\$967,821

total cost
avoidance



\$2,417

median cost
avoidance per fill

Specialty pharmacist review prior to renewal request proved effective in avoiding waste and unnecessary medication costs

FINANCIAL IMPACT OF INTEGRATED SPECIALTY PHARMACY EFFORTS TO AVOID ORAL ONCOLYTIC WASTE

Brooke D. Looney, PharmD, CSP¹| Jared Crumb, PharmD¹| Gabrielle Jones, PharmD candidate²
Ryan Moore, MS³| Leena Choi, PhD³| Autumn D. Zuckerman, PharmD, BCPS, AAHIVP, CSP¹
Kristen Wheelchel, PharmD, CSP¹

¹Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center

²Lipscomb University School of Pharmacy

³Department of Biostatistics, Vanderbilt University Medical Center




PURPOSE

To evaluate the impact on waste and cost avoidance associated with specialty pharmacist postponing requesting a prescription renewal in patients on oral oncolytics who have an upcoming follow-up (i.e., provider visit, labs, imaging) and sufficient medication supply.

METHODS

Single-center retrospective review, Vanderbilt University Medical Center
Patients filling oral oncolytics at Vanderbilt Specialty Pharmacy
January 1, 2020- January 31, 2021



Study Conclusion and Highlights

- Specialty pharmacist review prior to renewal request proved effective in avoiding waste and unnecessary medication costs
- Therapy was discontinued or changed in 98% of postponed refill renewals
 - Total cost avoidance was \$967,821
 - Median cost avoidance per fill \$2,417

RESULTS

Figure 1. Outcome of Follow-up (n=167)




Table 1. Top 5 Meds Associated with Cost Avoidance

Total Cost Avoidance	
Medication	Cost Avoidance
Temozolomide (n=66)	\$249,707.56
Palbociclib (n=11)	\$173,274.50
Everolimus (n=5)	\$ 84,815.64
Trifluridine-tipiracil (n=5)	\$ 69,186.40
Olaparib (n=4)	\$ 62,504.40
Median Cost Avoidance Per Fill	
Tucatinib (n=1)	\$25,891.20
Regorafenib (n=2)	\$23,598.96
Alpelisib (n=1)	\$22,466.64
Ruxolitinib phosphate (n=1)	\$18,692.40
Ribociclib succinate (n=1)	\$18,195.03

Figure 2. Median Cost Avoidance Per Fill by Outcome of Follow-up




Table 2. Cost Avoidance by Outcome of Follow-up

Outcome	Total
Medication discontinuation	\$489,843.34
Dose change	\$294,072.59
Medication change	\$113,035.16
Medication held	\$ 70,870.65
Total cost avoidance	\$967,821.74

ACKNOWLEDGEMENTS

We would like to acknowledge VSP Oncology and Hematology Specialty Pharmacists Stephanie White, PharmD and Katie Willford, PharmD, BCPS, CSP for their contributions to data review and collection.